Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

NCT03855917 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Sofosbuvir 400mg [Sovaldi]
DRUG: Glecaprevir/pibrentasvir (300mg/120mg)

Sponsor

Kirby Institute